Literature DB >> 18665766

Human umbilical cord blood-derived mesenchymal stem cells do not differentiate into neural cell types or integrate into the retina after intravitreal grafting in neonatal rats.

Andrew J Hill1, Isabel Zwart, Henry H Tam, Jane Chan, Cristina Navarrete, Ling-Sun Jen, Roberto Navarrete.   

Abstract

This study investigated the ability of mesenchymal stem cells (MSCs) derived from full-term human umbilical cord blood to survive, integrate and differentiate after intravitreal grafting to the degenerating neonatal rat retina following intracranial optic tract lesion. MSCs survived for 1 week in the absence of immunosuppression. When host animals were treated with cyclosporin A and dexamethasone to suppress inflammatory and immune responses, donor cells survived for at least 3 weeks, and were able to spread and cover the entire vitreal surface of the host retina. However, MSCs did not significantly integrate into or migrate through the retina. They also maintained their human antigenicity, and no indication of neural differentiation was observed in retinas where retinal ganglion cells either underwent severe degeneration or were lost. These results have provided the first in vivo evidence that MSCs derived from human umbilical cord blood can survive for a significant period of time when the host rat response is suppressed even for a short period. These results, together with the observation of a lack of neuronal differentiation and integration of MSCs after intravitreal grafting, has raised an important question as to the potential use of MSCs for neural repair through the replacement of lost neurons in the mammalian retina and central nervous system.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18665766     DOI: 10.1089/scd.2008.0084

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  18 in total

Review 1.  Stemming vision loss with stem cells.

Authors:  Valentina Marchetti; Tim U Krohne; David F Friedlander; Martin Friedlander
Journal:  J Clin Invest       Date:  2010-09-01       Impact factor: 14.808

2.  Mesenchymal stem cells for retinal diseases.

Authors:  Wei Xu; Guo-Xing Xu
Journal:  Int J Ophthalmol       Date:  2011-08-18       Impact factor: 1.779

Review 3.  Stem cell-based therapies for age-related macular degeneration: current status and prospects.

Authors:  Yalin Mu; Manli Zhao; Guangming Su
Journal:  Int J Clin Exp Med       Date:  2014-11-15

Review 4.  Current Status of Mesenchymal Stem/Stromal Cells for Treatment of Neurological Diseases.

Authors:  Milena B P Soares; Renata G J Gonçalves; Juliana F Vasques; Almir J da Silva-Junior; Fernanda Gubert; Girlaine Café Santos; Thaís Alves de Santana; Gabriela Louise Almeida Sampaio; Daniela Nascimento Silva; Massimo Dominici; Rosalia Mendez-Otero
Journal:  Front Mol Neurosci       Date:  2022-06-16       Impact factor: 6.261

5.  Scaffolds and stem cells: delivery of cell transplants for retinal degenerations.

Authors:  Karl E Kador; Jeffrey L Goldberg
Journal:  Expert Rev Ophthalmol       Date:  2012-10-01

6.  Good news-bad news: the Yin and Yang of immune privilege in the eye.

Authors:  John V Forrester; Heping Xu
Journal:  Front Immunol       Date:  2012-11-27       Impact factor: 7.561

7.  Transplantation of bone marrow-derived mesenchymal stem cells into the developing mouse eye.

Authors:  Eun-Shil Lee; Song-Hee Yu; Yu-Jin Jang; Dong-Youn Hwang; Chang-Jin Jeon
Journal:  Acta Histochem Cytochem       Date:  2011-10-06       Impact factor: 1.938

Review 8.  Stem cell treatment of degenerative eye disease.

Authors:  Ben Mead; Martin Berry; Ann Logan; Robert A H Scott; Wendy Leadbeater; Ben A Scheven
Journal:  Stem Cell Res       Date:  2015-02-24       Impact factor: 2.020

9.  Safety and Efficacy of Human Wharton's Jelly-Derived Mesenchymal Stem Cells Therapy for Retinal Degeneration.

Authors:  S N Leow; Chi D Luu; M H Hairul Nizam; P L Mok; R Ruhaslizan; H S Wong; Wan Haslina Wan Abdul Halim; M H Ng; B H I Ruszymah; S R Chowdhury; M L C Bastion; K Y Then
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

Review 10.  Stem cell therapies for age-related macular degeneration: the past, present, and future.

Authors:  Yalong Dang; Chun Zhang; Yu Zhu
Journal:  Clin Interv Aging       Date:  2015-01-14       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.